Clinical Benefit from Lenvatinib and Pembrolizumab Observed in Mullerian Adenosarcoma: A Case Report

A 32-year-old woman with chemorefractory mullerian adenosarcoma showed clinical benefit in response to administration of lenvatinib plus pembrolizumab. In this case report, we describe the course of her illness and her response to this treatment.

Detalles Bibliográficos
Autores principales: Alcindor, Thierry, Jung, Sungmi, Gilbert, Lucy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8293099/
https://www.ncbi.nlm.nih.gov/pubmed/34200874
http://dx.doi.org/10.3390/curroncol28030199

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8293099/
https://www.ncbi.nlm.nih.gov/pubmed/34200874
http://dx.doi.org/10.3390/curroncol28030199

Ejemplares similares